Titre
Hypertension in kidney transplantation: a consensus statement of the 'hypertension and the kidney' working group of the European Society of Hypertension.
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Halimi, J.M.
Auteure/Auteur
Ortiz, A.
Auteure/Auteur
Sarafidis, P.A.
Auteure/Auteur
Mallamaci, F.
Auteure/Auteur
Wuerzner, G.
Auteure/Auteur
Pisano, A.
Auteure/Auteur
London, G.
Auteure/Auteur
Persu, A.
Auteure/Auteur
Rossignol, P.
Auteure/Auteur
Sautenet, B.
Auteure/Auteur
Ferro, C.
Auteure/Auteur
Boletis, J.
Auteure/Auteur
Kanaan, N.
Auteure/Auteur
Vogt, L.
Auteure/Auteur
Bolignano, D.
Auteure/Auteur
Burnier, M.
Auteure/Auteur
Zoccali, C.
Auteure/Auteur
Liens vers les personnes
Liens vers les unités
ISSN
1473-5598
Statut éditorial
Publié
Date de publication
2021-08-01
Volume
39
Numéro
8
Première page
1513
Dernière page/numéro d’article
1521
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Publication Status: ppublish
Résumé
Hypertension is common in kidney transplantation recipients and may be difficult to treat. Factors present before kidney transplantation, related to the transplantation procedure itself and factors developing after transplantation may contribute to blood pressure (BP) elevation in kidney transplant recipients. The present consensus is based on the results of three recent systematic reviews, the latest guidelines and the current literature. The current transplant guidelines, which recommend only office BP assessments for risk stratification in kidney transplant patients should be reconsidered, given the presence of white-coat hypertension and masked hypertension in this population and the better prediction of adverse outcomes by 24-h ambulatory BP monitoring as indicated in recent systematic reviews. Hypertension is associated with adverse kidney and cardiovascular outcomes and decreased survival in kidney transplant recipients. Current evidence suggests calcium channel blockers could be the preferred first-step antihypertensive agents in kidney transplant patients, as they improve graft function and reduce graft loss, whereas no clear benefit is documented for renin-angiotensin system inhibitor use over conventional treatment in the current literature. Randomized control trials demonstrating the clinical benefits of BP lowering on kidney and major cardiovascular events and recording patient-related outcomes are still needed. These trials should define optimal BP targets for kidney transplant recipients. In the absence of kidney transplant-specific evidence, BP targets in kidney transplant recipients should be similar to those in the wider chronic kidney disease population.
PID Serval
serval:BIB_359B2536C5C6
PMID
Date de création
2021-06-14T12:55:32.274Z
Date de création dans IRIS
2025-05-20T14:56:12Z